Neuropsychiatric Symptoms and Psychotropic Medication Use Following SARS-Cov-2 Infection Among Elderly Residents in Long-Term Care Facilities

被引:0
|
作者
Cruz-Santiago, Diana [1 ,2 ]
Meng, Xiangfei [3 ,4 ]
Canac-Marquis, Michelle [5 ]
Sengupta, Avik [5 ]
Brassard, Jean-Philippe [5 ]
Pavey, Erik [5 ]
Girouard, Helene [1 ,6 ]
Vinh, Donald C. [5 ,7 ,8 ]
Gouin, Jean-Philippe [1 ,9 ]
机构
[1] Montreal Geriatr Inst, Res Ctr, Montreal, PQ, Canada
[2] Univ Montreal, Dept Family & Emergency Med, Montreal, PQ, Canada
[3] McGill Univ, Fac Med & Hlth Sci, Dept Psychiat, Montreal, PQ, Canada
[4] Douglas Res Ctr, Montreal, PQ, Canada
[5] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada
[6] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada
[7] Infect Dis & Immun Global Hlth Program, Montreal, PQ, Canada
[8] McGill Univ, Dept Med, Div Infect Dis, Hlth Ctr, Montreal, PQ, Canada
[9] Concordia Univ, Dept Psychol, 7141 Sherbrooke St West,PY170-14, Montreal, PQ H4B 1R6, Canada
关键词
neuropsychiatric symptoms; older adults; demen-; tia; COVID-19; nursing homes;
D O I
10.5770/cgj.28.770
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background SARS-CoV-2 infection can lead to persistent post-acute neuropsychiatric symptoms. Older adults with multimorbidity may be at increased risk of post-acute symptoms after COVID-19. The goals of the present study were to assess the associations of SARS-CoV-2 infection with neuropsychiatric symptoms and psychotropic medication prescription among older adults living in long-term care facilities. Methods Nursing home residents (n=111) participated in this threemonth longitudinal study. Nurse ratings of neuropsychiatric symptoms were conducted at baseline and at the three-month follow-up. SARS-CoV-2 infection status and psychotropic medication prescription were extracted from a medical chart review. Results About 73.9% of participants were infected with SARS-CoV-2 on average 480.49 (SD= 228) days before study enrollment. There were no significant changes in neuropsychiatric symptoms during the study follow-up period. Participants with a SARS-CoV-2 infection had more agitation compared to those who were never infected. However, this effect disappeared after adjusting for age, sex, history of psychiatric disorder, neurocognitive status, and multimorbidity. Participants with SARS-CoV-2 had a higher number of psychotropic medication prescription. This effect was driven by increased use of antidepressants and antipsychotic medications. Conclusion Both acute and short-term neuropsychiatric symptoms associated with COVID-19 may contribute to long-term psychoactive polypharmacy among older adults living in longterm facilities.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [41] Reports of three long-term lung disease following SARS-CoV-2 infection
    Piantoni, Silvia
    Salada, Luisa
    Colombo, Enrico
    Mendeni, Monia
    Damiolini, Ezio
    Gatta, Diego
    Richini, Donata
    Furloni, Roberto
    Airo, Paolo
    Scarsi, Mirko
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (05) : 2585 - 2587
  • [42] Long-term neurological sequelae of SARS-CoV-2 infection
    Al-Aly, Ziyad
    NATURE MEDICINE, 2022, 28 (11) : 2269 - 2270
  • [43] Long-term neurological sequelae of SARS-CoV-2 infection
    Nature Medicine, 2022, 28 : 2269 - 2270
  • [44] Asymptomatic bacteriuria among the elderly residents of long-term care facilities in Taiwan
    Chang, Hsiao-Ting
    Juang, Shiow-Jen
    Liang, Yao-Jen
    Lin, Ming-Hwai
    Ho, Mei-Man
    Chen, Chun-Ku
    Hwang, Shinn-Jang
    AGE AND AGEING, 2012, 41 (06) : 795 - 798
  • [45] Treatment of Cardiovascular Diseases Among Elderly Residents of Long-term Care Facilities
    Kantoch, Anna
    Gryglewska, Barbara
    Wojkowska-Mach, Jadwiga
    Heczko, Piotr
    Grodzicki, Tomasz
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (05) : 428 - 432
  • [46] Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population
    Wang, Yunhe
    Su, Binbin
    Xie, Junqing
    Garcia-Rizo, Clemente
    Prieto-Alhambra, Daniel
    NATURE HUMAN BEHAVIOUR, 2024, 8 (06) : 1076 - 1087
  • [47] Clinical picture and long-term symptoms of SARS-CoV-2 infection in an Italian pediatric population
    Bloise, Silvia
    Isoldi, Sara
    Marcellino, Alessia
    De Luca, Enrica
    Dilillo, Anna
    Mallardo, Saverio
    Martucci, Vanessa
    Sanseviero, Mariateresa
    Del Giudice, Emanuela
    Iorfida, Donatella
    Leone, Rita
    Testa, Alessia
    Frasacco, Beatrice
    Gizzone, Pietro
    Ciolli, Claudia Proietti
    Sinceri, Alessandro
    Zuliani, Francesca
    Zanardi, Elena
    Gambarotto, Anna
    Grandinetti, Anna Lisa
    Ventriglia, Flavia
    Lubrano, Riccardo
    ITALIAN JOURNAL OF PEDIATRICS, 2022, 48 (01)
  • [48] Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
    Krutikov, Maria
    Palmer, Tom
    Tut, Gokhan
    Fuller, Chris
    Shrotri, Madhumita
    Williams, Haydn
    Davies, Daniel
    Irwin-Singer, Aidan
    Robson, James
    Hayward, Andrew
    Moss, Paul
    Copas, Andrew
    Shallcross, Laura
    LANCET HEALTHY LONGEVITY, 2021, 2 (06): : E362 - E370
  • [49] Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)
    Stirrup, Oliver
    Shrotri, Madhumita
    Adams, Natalie L.
    Krutikov, Maria
    Nacer-Laidi, Hadjer
    Azmi, Borscha
    Palmer, Tom
    Fuller, Christopher
    Irwin-Singer, Aidan
    Baynton, Verity
    Tut, Gokhan
    Moss, Paul
    Hayward, Andrew
    Copas, Andrew
    Shallcross, Laura
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):
  • [50] Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV
    Antoni, Melania Degli
    Maifredi, Giovanni
    Storti, Samuele
    Tiecco, Giorgio
    Di Gregorio, Marco
    Rossi, Benedetta
    Gasparotti, Cinzia
    Foca, Emanuele
    Castelli, Francesco
    Quiros-Roldan, Eugenia
    INFECTION, 2024, 52 (06) : 2339 - 2350